Premium
The Clinical Utility of Precision Medicine: Properly Assessing the Value of Emerging Diagnostic Tests
Author(s) -
Shen B,
Hwang J
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.236
Subject(s) - clinical pharmacology , outlier , intensive care medicine , medicine , value (mathematics) , precision medicine , medical physics , actuarial science , computer science , pharmacology , economics , pathology , machine learning , artificial intelligence
Assessments of the clinical utility of biomarkers and genomic tests often ignore individual utility and fail to account for downstream changes to the care delivery model. Tests that identify outliers are often undervalued in favor of those that help direct treatment for the “average” patient. By reducing uncertainty, these tests also enable lower‐cost providers and even patients to assume increased responsibility for care in more convenient and affordable settings. Clinical Pharmacology & Therapeutics (2010) 88 6, 754–756. doi: 10.1038/clpt.2010.236